Background: Traditional Chinese Medicine (TCM) has gradually drawn the attention of clinicians as an alternative choice for insomniacs and TCM Yangxin Anshen Therapy (TYAT) is a crucial therapy of treating insomniacs. The purpose of this study was to evaluate the efficacy and safety of TYAT for insomnia.
Introduction
Insomnia is a subjective experience characterized by difficulty falling asleep, impaired sleep maintenance, early awakening, decreased sleep quality, and reduced sleep time along with daytime dysfunction. [1, 2] The proportion of people suffering from insomnia in China has reached as high as 15%, which is lower than that in Western countries, but similar to that in other Asian countries. [3] [4] [5] More noteworthy than that is insomnia has a bearing on increased risk of hypertension, [6, 7] diabetes, [8] [9] [10] chronic kidney disease, [11, 12] and dementia. [13] Besides, in terms of economic costs, insomnia also imposes a huge burden on social welfare. [14] At present, clinical medications for insomniacs in China mainly include benzodiazepine drugs, non-benzodiazepine drugs, melatonin receptor agonists, orexin receptor antagonist, and the antidepressant drugs with hypnotic effects. [2] Among them, benzodiazepines are still one of the most commonly used drugs in clinical treatment of insomnia. Benzodiazepines are the most frequently medication for insomnia in the Korean. [15] Based on the analysis of data from 22 hospitals in Beijing, China, the results showed that benzodiazepine receptor agonists was the most widely used drug, accounting for 58.49% of prescriptions, of which benzodiazepine drugs accounted for 38.64% and nonbenzodiazepine drugs accounted for 19.85%. [16] However, adverse reactions of these drugs restrict their clinical application. [1, 2, 17] Take benzodiazepines as an example, the use of it increases the risk of Alzheimer's disease. [18] TYAT (tranquilizing the mind by nourishing the heart therapy, named Yangxin Anshen in Chinese pinyin) is one of the crucial therapeutic principles for insomnia in TCM which contains a series of Chinese herbal prescriptions with the effect of nourishing the heart and tranquilizing the mind. In the past meta-analysis, [19, 20] all Chinese herbal medicines have been regarded as the same treatment method, which is inconsistent with the practice of TCM diagnosis and treatment, resulting in a high degree of heterogeneity and conclusions with limited significance. The purpose of this article was to summarize and analyze the clinical effect of TYAT on insomnia by means of high-quality researches.
Methods

Protocol register
This protocol of systematic review and meta-analysis has already been registered on the PROSPERO platform (https://www.crd. york.ac.uk/PROSPERO/) with an assigned registration number CRD42019135115. The detailed protocol [21] has been published, so this article will not repeat the methods of collecting and analyzing data.
Ethics
In view of the fact that this is a secondary study based on published literature, no further ethical approval is required.
Results
Literature search and screening results
A total of 3457 articles were retrieved according to the search strategy and no additional articles were identified by manual search. Of these, 682 were retrieved by CBM, 710 by CNKI, 879 by VIP, 923 by Wanfang, 57 by PubMed, 115 by EMBASE, and 91 by CENTRAL. A total of 1505 duplicates were found. After that, 1665 literature were excluded through the title and abstract, including 50 animal experiments, 21 reviews, 284 combined with other diseases, 131 clinical experiences, 480 non-RCTs, 11 protocols, and 688 other therapies. For a further step, the authors screened the remaining 287 full-texts for identification, and 246 articles were removed with reasons: 2 protocols, 107 non-RCT, 13 non-fixed prescriptions, 91 utilizing other therapies, and 33 combined with other diseases. The resulting of 41 articles were then subjected to Cochrane risk of bias assessment, of which 27 studies were excluded because of a high risk of bias (less than 4 scores), and 14 studies [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] were included in the meta-analysis finally.
Quality evaluation of included studies
The Cochrane bias risk score of the included studies ranged from 4 to 6. The included articles were all RCTs, and all mentioned randomly grouping, of which 12 studies described the specific method of randomization, but the remaining 2 [32, 33] studies did not mention the explicit randomization method. Four studies [22, 25, 26, 30] described specific methods of allocation concealment, such as central randomization, envelopes. Seven studies [22, 25, 26, [30] [31] [32] 34] used a double-blind protocol. Three studies [22, 26, 30] performed a blinded evaluation of study outcomes. Selective reporting of study results and other sources of bias were not identified in the included studies. The bias summary and the bias for each study show as below (Figs. 1 and 2). Table 1 presents characteristics table extracted from the 14 articles included. Three [26, 30, 33] of them were published in English journals, and the left 11 were published in Chinese. The 14 studies incorporated into the meta-analysis involved a total of 1549 patients accurately diagnosed with insomnia (778 in the experimental group and 771 in the control group). The sample of patients ranged from 47 to 198, and all studies were undertaken in China. The experimental group was given TYAT, while the control group was given the placebo, benzodiazepines, or non-benzodiazepine hypnotics. Treatment duration varied from 2 to 6 weeks. Four articles [22, 28, 30, 31] reported the follow-up time, which was 7-14 days. The authors have listed the components of prescriptions used in each literature in Table 2 and briefly analyzed the frequency of each component (see Table 3 ).
Literature characteristics
3.4. Clinical efficacy 3.4.1. TYAT vs placebo. Two studies [31, 32] reported the improvement of PSG after treatment, which mainly included 4 parameters: total sleep time (TST), sleep efficiency (SE), sleep of latency (SOL), and wake time after sleep onset (WASO). The results of heterogeneity analysis for the 4 parameters were: P = .35, I 2 = 0%; P = .54, I 2 = 0%; P = .71, I 2 = 0%; P = .80, I 2 = 0%. Therefore, we used a fixed effect model. The results (mean difference (MD) = 5.16, 95% confidence interval (CI): 3.09,7.23, P < .00001; MD = 1.21, 95% CI:0.80, 1.61, P < .00001;MD = À 2.87, 95% CI:À4.12, À1.62, P < .00001; MD = À2.28, 95% CI:À4.07, À0.49, P = .01) of the meta-analysis suggested that the clinical efficacy of TYAT, according to PSG parameters, was significantly better than that of placebo in treating insomnia (See Figs. [3] [4] [5] [6] . Five studies [22, 25, 30, 32, 34] reported the improvement of PSQI scale after treatment. Results of heterogeneity analysis were: P < .00001, I 2 = 90%, which meant a pronounced heterogeneity existed among studies. In the study of Lin, [30] the intervention of the treatment group was "Wuling Capsule", which belongs to the extract of Chinese herbal medicine, and the experimental intervention of the others belongs to the TCM compound prescription. Thus, we excluded this study, which may be the source of heterogeneity, and subgroup analysis was performed according to the duration of treatment. We used a fixed effect model, depending on the results of the heterogeneity analysis (P = .80, I 2 = 0%; P = .90, I 2 = 0%). Upon the results of metaanalysis (MD = À2.00, 95% CI: À2.93, À1.07, P < .0001; MD = À4.05, 95% CI: À4.86, À3.23, P < .00001), the clinical efficacy of TYAT in the treatment of insomnia was significantly better than placebo. Moreover, with the extension of the course of treatment, the efficacy difference between 2 groups was seemly more and more significant ( Fig. 7) .
Two studies [25, 34] reported the improvement of TCM curative efficacy after treatment, and the results of heterogeneity analysis were: P = .68, I 2 = 0%. Therefore, we used a fixed effect model. Meta-analysis results (risk ratio (RR) = 1.99,95% CI: 1.53, 2.58, P < .00001) suggested that: TCM curative efficacy of TYAT for insomnia was significantly better than that of placebo (see Fig. 8 ).
Two studies [22, 25] reported the improvement of PSQI curative efficacy after the intervention. Results of heterogeneity analysis were P = .02, I 2 = 81%. There was great heterogeneity between studies, therefore, we only did a qualitative analysis. As showed in the results of the 2 studies, PSQI curative efficacy of insomnia patients treated with TYAT was superior to that of placebo.
TYAT vs benzodiazepines.
Only 1 study reported changes in PSG after treatment. From the results of Hu study, [26] we found that TYAT could significantly prolong TST and slow Five studies [23, 24, [26] [27] [28] reported the improvement of PSQI scale after treatment, and the results of the heterogeneity test (P < .00001, I 2 = 95%) suggested a high heterogeneity existed among studies. Therefore, only qualitative descriptive analysis was implemented. Three studies [24, 27, 28] concluded that there was no significant difference between TYAT and benzodiazepines. Another 2 [23, 26] concluded that there was a significant difference between 2 groups in improving the PSQI scale and that TYAT was superior to benzodiazepines.
Three studies [23, 24, 28] reported the improvement of TCM curative efficacy after treatment, and the consequences of heterogeneity analysis were: P = .25, I 2 = 27%. Therefore, we implemented a fixed effect model. The results of meta-analysis (RR = 1.09, 95%CI: 0.97, 1.22, P = .15) showed that there was no significant difference in TCM curative efficacy of TYAT for insomnia compared with benzodiazepines (see Fig. 9 ).
Four studies [23, 24, 27, 28] reported the improvement of PSQI curative efficacy after treatment, and the results of heterogeneity analysis were P = .41, I 2 = 0%. Therefore, we adopted a fixed effect model. The results of meta-analysis (RR = 1.05, 95%CI: 0.95,1.16, P = .30) showed that there was no significant difference in PSQI curative efficacy of TYAT for insomniacs compared with benzodiazepines (see Fig. 10 ).
TYAT versus non-benzodiazepine hypnotics.
Two studies [29, 35] reported the improvement of PSQI scale after treatment, whose results of heterogeneity analysis were: P < .00001, I 2 = 99%. Therefore, we employed a random effect model. There was no significant difference between TYAT and non-benzodiazepines in improving PSQI scores based on the results of meta-analysis (MD = À1.16, 95%CI: À3.80,1.49, P = .39) (see Fig. 11 ).
Two studies [29, 35] reported the improvement of PSQI curative efficacy after treatment. In line with the results of heterogeneity analysis (P = .006, I 2 = 87%), a random effect model was adopted. There was no significant difference in PSQI curative efficacy between TYAT and non-benzodiazepines for insomniacs on the basis of meta-analysis (RR = 1.08, 95%CI:0.86, 1.36, P = .52) (see Fig. 12 ).
Adverse events
Thirteen out of 14 studies reported adverse events. Adverse events of TYAT were mainly manifested as fatigue, dry mouth, abdominal distension, diarrhea, constipation, and so on. The main adverse events of benzodiazepines were fatigue, dry mouth, dizziness, drowsiness, hangover, and other symptoms. The adverse events of non-benzodiazepines were mainly dry mouth, bitter mouth, dizziness, numbness of lips, and so on. Adverse events reported in all recruited studies were mild, and no lifethreatening adverse events were found. Specific adverse events for each study were summarized in Table 4 [28] 2013 CCMD-3 60 (27) 45 (23) [27] 2013 CCMD-3 60 (23) [23] 2016 CCMD-3 52 (29) 52 (24) [26] 2015 ICD-10 60 (20) [34] 2011 CCMD-3 21 (4) 26 (8) 41.82 ± 12.88 42.37 ± 11.64 7.9 ± 3.84y 5.7 ± 2.53y XSN Placebo 3w NM Lin [30] 2013 ICD-10 99 (28) 99 (26) 18-60 18-60 NM NM WC Placebo 4w 2w Rong [31] 2017 DSM-IV-TR 78 (25) 80 (26) 47 ± 11 46 ± 10 11.4 ± 9.3y 8.6 ± 6.7y MS Placebo 4w 7-14d Yuan [22] 2013 CCMD-3 30 (7) 30 (4) Liu [25] 2016 CCMD-3 57 (16) 58 (20) The ingredients of each prescription.
Studies Prescription Constitution Usage Formulation
Xia [33] XNSP Radix Astragali (Huang Qi) Suan Zao Ren is a relatively safe hypnotic drug for insomniacs, whose secondary metabolites have been proved in vitro and in vivo researches to produce the effect of sedation and hypnosis by regulating GABAergic activity and 5-HT system. [36] In clinical research, Zhou et al [37] collected and analyzed the high-quality RCTs on the treatment of insomnia with formulations containing Suan Zao Ren, and found that it is an effective replacement therapy for insomniacs. Tanshinones may be a sedative hypnotic active substance extracted from Dan Shen, which may be more suitable for insomniacs accompanied by cardiovascular diseases for its cardiovascular activity. [38] Besides, Dan Shen and Suan Zao Ren can play a significant synergistic role in reducing latent sleep and prolonging TST. [38] It is worth noting that Dan Shen appeared 3 times in total in enclosed 14 formulations and Suan Zao Ren was simultaneously used in 3 formulations containing Dan Shen. Yunfeng Li team discovered that Yuanzhi-1, a triterpenoid saponin component extracted from Yuan Zhi, may potentially become a new triple reuptake inhibitor because of its antidepressant-like activity. [39, 40] Insomnia was largely bound up with a higher risk of depression and insomniacs were more than twice as likely to suffer from depression as non-insomniacs. [41] Ye Jiao Teng, Yuan Zhi, Suan Zao Ren, Fu Ling, Gan Cao, Dang Gui, Bai Zi Ren, Di Huang, and Wu Wei Zi were frequently applied to treating insomnia in TCM. [42, 43] Among them, Ye Jiao Teng and Suan Zao Ren which are categorized as Anshen herbals in TCM are designated as Sovereign or Minister herbals, but Fu Ling and Gan Cao used as an Assistant or Courier herbal have no definite effect of sedation. [42] Wu Wei Zi and its extracts can produce effective sedative and hypnotic bioactivity and antidepressant-like activity, the mechanism of sedative and hypnotic bioactivity mainly associating with the serotonergic and GABAergic system. [44] [45] [46] [47] [48] 
Limitations
The retrieved studies were only those published in Chinese or
English at present, and there may be unpublished negative conclusions, which may bring about potential publication bias. In addition, because the number of studies in each subgroup was less than 10, the funnel plot was not implemented to evaluate the publication bias in our study. 2. According to the assessment of Cochrane risk bias, we did recognize that there were some methodological limitations which may have an impact on the reliability of the results. The authors noted that appropriate allocation concealment was only used in 4 studies, and adequate randomization methods in 12 studies. The poor status of randomization may have contributed to the low methodological quality or low reporting quality, which may have inflated the clinical efficacy evaluation. 3. Although double blinding is encouraged in RCTs, it is difficult to practice it for herbal intervention because of the different shape, smell, taste, and administration of herbal from pharmacotherapy [20] . Considering this challenge, it is understandable that double blinding protocol was implemented in merely 7 studies. Insufficient blinding was also the cause of overestimation of the effect size, which cannot be ignored. 4. There were certain differences in the diagnose criteria, interventions, dosage, duration of medication, and the judgment of efficacy, which may cause heterogeneity in this meta-analysis. To make matters worse, clinical, and methodological heterogeneity could not be well settled by subgroup analysis. 5. Due to the relatively short observation period, the long-term efficacy of TYAT could not be further assessed. Arguably, however, the long-term treatment of insomnia using hypnotics is clinically relevant because insomnia typically returns following withdrawal. [49] 6. Nowadays, PSG is the most advanced instrument for the diagnosis of many sleep disorders. In terms of accuracy, the PSG is the best method, reporting the most complete and precise information. [50] The fact is, however, that only 3 studies chose PSG as the outcome measure of the intervention. 
Implications for future research
In light of the above limitations, many implications arose out of related research. Firstly, we are required to refine the trial protocol and conduct more high-quality, multi-center, largesample RCTs. Before that, the prospective registration of clinical trials was needed. Registries can identify potential problems before research begins, such as allocation concealment, randomization methods, and blind methods, thereby improving the quality of clinical trials. Secondly, syndrome differentiation is a unique diagnostic method for the classification of diverse individual pathological states under the guidance of TCM theory, which can be regarded as a further stratification of diseases. [51] Treatment based on syndrome differentiation is the key to enhance clinical efficacy. In TCM, different syndromes correspond to different therapeutic principles and prescriptions. Therefore, comprehensive searches and appraisals of the evidence for different therapeutic principles and TCM prescriptions are necessary for the future. Thirdly, prolonging the trial period appropriately and improving the follow-up protocol, so that we can observe the long-term efficacy and safety of TYAT. Finally, PSG is of great significance to the study of sleep. In future relevant research, investigators should consider PSG as one of the outcome measurements as far as possible.
Conclusion
In summary, TYAT is an effective alternative therapy for insomnia, and its clinical application is relatively safe. Due to the uneven quality of the included literature, further multicenter, large-sample, high-quality clinical trials are still needed for validation in the future. Only in this way are we able to obtain a more decisive conclusion about the clinical efficacy and safety of TYAT for insomnia. Adverse events in the included studies.
Intervention Adverse events
Studies Trial Control Trial group Control group P value
Xia [33] XNSP Estazolam profuse urination (n = 4); dry mouth (n = 2); sweating (n = 1) dizziness (n = 5); asthenia (n = 4); lethargy (n = 4); dry mouth (n = 3); cloudy vision (n = 2) P < .01
Wang [24] YYAST Estazolam nausea and abdominal distension (n = 1) dizziness and fatigue (n = 3) P < .05 Gan [27] ZAC Alprazolam mild fatigue (n = 6); diarrhea (n = 2) fatigue (n = 12); dizziness (n = 11); drowsiness (n = 7); hangover (n = 2) NM Shi [23] QAD Estazolam none dry mouth (n = 3); lethargy (n = 2); dizziness (n = 2); fatigue (n = 1) NM Hu [26] SZR-ZZC Lorazepam diarrhea (n = 1) dizziness (n = 2) NM Huang [35] ASG Zopiclone none none P > .05 Wang [29] ZAC Eszopiclone pantothenic acid (n = 1); labial numbness (n = 1) bitter mouth and dry mouth (n = 5); dizziness and headache (n = 3); labial numbness (n = 1) P = .027
Wang [32] ZT Placebo none none NM Jing [34] XSN Placebo none none NM Lin [30] WC Placebo dizziness (n = 2); numbness in hands and feet (n = 1); dry mouth (n = 2); constipation (n = 1); stomach bloating (n = 2); stomach pain (n = 1); diarrhea (n = 1) dizziness (n = 1); dry mouth (n = 2); constipation (n = 1); stomach pain (n = 1); diarrhea (n = 1); drowsiness after medication at noon (n = 1) P = .386
Rong [31] MS Placebo fatigue (n = 6); dry mouth (n = 3); headache (n = 4); nasal congestion (n = 2); muscle stiffness (n = 2); constipation (n = 2); depressed mood (n = 1) fatigue (n = 6); dry mouth (n = 5); lack of concentration (n = 5); nasal congestion (n = 2); muscle stiffness (n = 1); constipation (n = 1); depressed mood (n = 2); lethargy (n = 1) P = . 59
Yuan [22] MG+ Estazolam Placebo+ Estazolam none none NM Liu [25] XSC 
